Simple Summary Chronic myeloid leukemia (CML) is a blood cancer currently well
managed with drugs that inhibit the protein responsible for the disease. However, some …

Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for
chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for∼ 15% of
all leukemia. Progress of the disease from an indolent chronic phase to the more aggressive …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

The BCR-ABL1 fusion gene, which causes aberrant kinase activity and uncontrolled cell
proliferation, is the hallmark of chronic myeloid leukemia (CML). The development of …

The hematopoietic neoplasm chronic myeloid leukemia (CML) is a rare disease caused by
chromosomal reciprocal translocation t (9; 22)(q34: q11) with subsequent formation of the …

Introduction While the acquisition of mutations in the ABL1 kinase domain (KD) has been
identified as a common mechanism behind tyrosine kinase inhibitor (TKI) resistance, recent …

Small molecule therapy is a critical component of targeted anticancer treatment, with
tyrosine kinase inhibitors (TKIs) being the first compounds to treat the clonal Chronic …

We performed whole-exome sequencing in samples representing accelerated phase (AP)
and blastic crisis (BC) in a subject with chronic myeloid leukemia (CML). A total of 12.74 Gb …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …